Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors
Menée dans un contexte américain, cette étude compare le rapport coût-efficacité de trois stratégies thérapeutiques utilisant un agent chimiothérapeutique en monothérapie chez des patientes atteintes d'un cancer du sein triple négatif de stade métastatique ou réfractaire à une thérapie endocrinienne
Policy proposals addressing the high cost of treating cancer are among the most persistently controversial topics in oncology. The rising national economic burden of cancer in an aging population, combined with skyrocketing costs for cancer diagnostics, therapies, and hospital-based care, all strain patient, family, and health system budgets.1 Few would disagree with the sentiment that controlling the rate of spending growth is fundamental and essential for societies wishing to improve access and reduce inequity in cancer care.
Journal of Clinical Oncology , éditorial, 2021